Alpha-MSH vs Dalargin

Melanocortin peptide; activates MC1R (pigmentation/anti-inflammatory), MC3R (energy balance), MC4R (appetite); suppresses NF-κB and pro-inflammatory cytokines

α-Melanocyte-stimulating hormone (α-MSH) is an endogenous 13-amino-acid peptide derived from proteolytic processing of proopiomelanocortin (POMC) that acts through melanocortin receptors (MC1R–MC5R), with biological roles including skin pigmentation, anti-inflammatory signaling, thermoregulation, and energy homeostasis. Its anti-inflammatory actions are mediated principally through MC1R and MC3R activation, leading to inhibition of NF-κB-dependent cytokine production, reduction of pro-inflammatory mediators including IL-1β and TNF-α, and modulation of leukocyte activity in both peripheral and central nervous system compartments. Research published in the Annals of the New York Academy of Sciences has characterized the mechanisms of α-MSH's anti-inflammatory activity in vivo and in vitro, and subsequent work has described new insights into its immunomodulatory functions and therapeutic potential in inflammatory conditions. α-MSH is a research compound with no FDA approval for any indication; no human clinical trials have established safety or efficacy for exogenous α-MSH administration in anti-inflammatory, neuroprotective, or other therapeutic contexts. Alpha-MSH and the melanocortin peptide family α-MSH is the prototype endogenous ligand for the melanocortin receptor family — five receptors (MC1R–MC5R) with distinct tissue distribution and functions. The pharmacological development of synthetic melanocortin analogues has produced several clinically and commercially relevant compounds derived from or inspired by α-MSH: Melanotan I (afamelanotide, MC1R-selective, approved as Scenesse for erythropoietic protoporphyria), Melanotan II (non-selective, superpotent, never approved; extensively used in research), and PT-141/bremelanotide (cyclized Melanotan II analogue, FDA-approved as Vyleesi for female hypoactive sexual desire disorder via MC3R/MC4R). α-MSH itself serves as the structural reference point for this lineage — the pharmacophore binding sequence (His-Phe-Arg-Trp) shared by all active melanocortin analogues is derived from α-MSH residues 6–9. Appetite regulation and obesity research: α-MSH's role in energy homeostasis is mediated through MC4R activation in the hypothalamus, where it acts as an endogenous satiety signal opposing the appetitive effects of AgRP (agouti-related protein). Loss-of-function MC4R mutations are the most common monogenic cause of severe early-onset obesity, establishing the α-MSH/MC4R pathway as a validated target for pharmacological weight management. Setmelanotide (Imcivree), an MC4R agonist, is FDA-approved for obesity caused by MC4R pathway deficiency mutations (POMC deficiency, PCSK1 deficiency, leptin receptor deficiency) — a direct pharmacological descendant of the α-MSH mechanism.

Binds delta and mu opioid receptors with peripheral preference due to limited CNS penetration. Reduces gastric acid secretion, promotes mucosal blood flow, and inhibits ulcer formation via prostaglandin-mediated pathways.

Dalargin (D-Ala2-Leu5-Arg6-enkephalin) is a synthetic hexapeptide opioid receptor agonist developed in the Soviet Union as a stable enkephalin analog, designed with D-amino acid substitution to resist enzymatic degradation, and investigated for gastroprotective and analgesic properties in animal models and limited Russian clinical use. Dalargin binds mu and delta opioid receptors and is proposed to exert gastroprotective effects through opioid receptor-mediated suppression of gastric acid secretion, stimulation of mucosal prostaglandin synthesis, and promotion of epithelial repair, with additional central analgesic activity demonstrated in preclinical studies. Published evidence in Western PubMed-indexed journals is limited to animal studies demonstrating gastroprotective activity against NSAID-induced mucosal damage; the compound has been used in Russian clinical practice for peptic ulcer disease, but no randomized controlled trials meeting current methodological standards have been published in English-language indexed journals. Dalargin has no FDA approval and no regulatory approval in any Western jurisdiction; it is an obscure research compound whose evidence base is largely confined to Soviet-era and Russian-language literature, and its safety and efficacy profile in humans has not been validated by independent clinical investigation.